BioMarin Pharmaceutical Inc. (BIT:1BMRN)

Market Cap	8.84B
Revenue (ttm)	2.61B
Net Income (ttm)	559.64M
Shares Out	n/a
EPS (ttm)	2.89
PE Ratio	15.80
Forward PE	11.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147
Average Volume	23
Open	48.67
Previous Close	45.19
Day's Range	46.50 - 48.67
52-Week Range	43.05 - 67.42
Beta	n/a
RSI	37.44
Earnings Date	Oct 24, 2025

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 3,040
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1BMRN

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD